<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679883</url>
  </required_header>
  <id_info>
    <org_study_id>GLH8NDE-201</org_study_id>
    <nct_id>NCT04679883</nct_id>
  </id_info>
  <brief_title>Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of GLH8NDE in Patients With Dry Eye Disease</brief_title>
  <official_title>A Phase 2 Multicenter, Randomized, Double-blinded, Placebo-controlled Trial to Evaluate the Efficacy and Safety of GLH8NDE in Patients With Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GL Pharm Tech Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GL Pharm Tech Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled phase 2 clinical trial to&#xD;
      evaluate the efficacy and safety of GLH8NDE in patients with Dry Eye Disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of Total Corneal Staining Score (TCSS)</measure>
    <time_frame>Between 1 day before first IP administration and 4 weeks</time_frame>
    <description>To 4 weeks after baseline visit using NEI scale (total between 0 and 15 scores)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of Total Corneal Staining Score (TCSS)</measure>
    <time_frame>Between 1 day before first IP administration and 2, 8, 12 weeks</time_frame>
    <description>To 2, 8, 12 weeks after baseline visit using NEI scale (total between 0 and 15 scores, higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Inferior Corneal Staining Score (ICSS)</measure>
    <time_frame>Between 1 day before first IP administration and 2, 4, 8, 12 weeks</time_frame>
    <description>To 2, 4, 8, 12 weeks after baseline visit using NEI scale (total between 0 and 15 scores, higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Conjunctival Staining Score</measure>
    <time_frame>Between 1 day before first IP administration and 2, 4, 8, 12 weeks</time_frame>
    <description>To 2, 4, 8, 12 weeks after baseline visit using NEI scale (total between 0 and 18 scores, higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Tear Film Break-up time(TFBUT)</measure>
    <time_frame>Between 1 day before first IP administration and 2, 4, 8, 12 weeks</time_frame>
    <description>To 2, 4, 8, 12 weeks after baseline visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Schirmer I test</measure>
    <time_frame>Between 1 day before first IP administration and 2, 4, 8, 12 weeks</time_frame>
    <description>To 2, 4, 8, 12 weeks after baseline visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of 5-item dry questionnaire (DEQ-5)</measure>
    <time_frame>Between 1 day before first IP administration and 2, 4, 8, 12 weeks</time_frame>
    <description>To 2, 4, 8, 12 weeks after baseline visit (total between 0 and 22 socres, higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Ehlers-Danlos Syndrome (EDS) by Visual Analogue Scale (VAS)</measure>
    <time_frame>Between 1 day before first IP administration and 2, 4, 8, 12 weeks</time_frame>
    <description>To 2, 4, 8, 12 weeks after baseline visit (total between 0 and 100 scores, highter scores mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Ccular Discomfort Score(ODS)</measure>
    <time_frame>Between 1 day before first IP administration and 2, 4, 8, 12 weeks</time_frame>
    <description>To 2, 4, 8, 12 weeks after baseline visit (total 0 and 4 scores, higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>GLH8NDE 5% and GLH8NDE Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three times each 1 drop a day, total 6 times 1 drop of GLH8NDE 5% and GLH8NDE Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLH8NDE 5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total 6 times 1 drop of GLH8NDE 5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLH8NDE Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Total 6 times 1 drop of GLH8NDE Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% GLH8NDE</intervention_name>
    <description>5% GLH8NDE as eye drops</description>
    <arm_group_label>GLH8NDE 5%</arm_group_label>
    <arm_group_label>GLH8NDE 5% and GLH8NDE Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo as eye drops</description>
    <arm_group_label>GLH8NDE 5% and GLH8NDE Placebo</arm_group_label>
    <arm_group_label>GLH8NDE Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject who is the age of older than 19 years at the screeing visit&#xD;
&#xD;
          -  Subject who has symptom at least one or more as below for six months(Irritation,&#xD;
             foreign body sensation, burning, mucus discharge, blurring, itching, photophobia,&#xD;
             tired or heavy feeling and pain)&#xD;
&#xD;
          -  Subject with dry eye syndrome who meet all of the following criteria among the left&#xD;
             and/or right eyes at the time of screening and baseline visit.&#xD;
&#xD;
               1. Over six grade as fluorescein corneal staining by National Eye Institute scale&#xD;
&#xD;
               2. Schirmer I test ≤ 10 mm/5 min.&#xD;
&#xD;
               3. TFBUT ≤ 6 seconds&#xD;
&#xD;
          -  At the screening and baseline visit, the intraocular pressure(IOP) of both eyes is&#xD;
             more than 5 mmHg and below 22 mmHg&#xD;
&#xD;
          -  At the screening and baseline visit, biocular best corrected visual acuity(BCVA) are&#xD;
             over 0.2(=+0.7 logMAR or Snellen 20/100)&#xD;
&#xD;
          -  At the baseline visit, over 80% administration compliance during run-in period as&#xD;
             placebo in single blind&#xD;
&#xD;
          -  Subject who signed and dated the informed consent form after understanding fully to&#xD;
             hear a detailed explanation in the clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ophthalmic diseases that may confuse the interpretation of clinical trial results,&#xD;
             such as clinically significant corneal surface disease, abnormal corneal sensitivity,&#xD;
             and abnormal tearing&#xD;
&#xD;
          -  Subject with wounds caused by refractive surgery such as LASIK surgery (However, if it&#xD;
             does not affect the clinical trial compliance and result evaluation according to the&#xD;
             investigator's judgment, participation is possible.)&#xD;
&#xD;
          -  Subject with the following concomitant diseses at screening visit.&#xD;
&#xD;
               1. Eyelid disease (blepharopathy, blepharolysis, valgus, varus valgus, etc.),&#xD;
                  conjunctival relaxation, cataracts, and eye diseases requiring treatment&#xD;
&#xD;
               2. Sjogren's syndrome and secondary Sjogren's syndrome (rheumatoid arthritis,&#xD;
                  systemic lupus erythematosus, etc.)&#xD;
&#xD;
               3. Diabetes not controlled despite appropriate treatment (hemoglobin A1c (HbA1c)&gt;&#xD;
                  9%)&#xD;
&#xD;
               4. Subject with the following systemic diseases that are not controlled High blood&#xD;
                  pressure that is not controlled despite administration of antihypertensive drugs&#xD;
                  (systolic blood pressure (SBP)/diastolic blood pressure (DBP)&gt;160/100 mmHg)&#xD;
                  Clinically significant cardiopulmonary disease despite appropriate treatment&#xD;
&#xD;
               5. Acute active hepatitis A, active hepatitis B or C&#xD;
&#xD;
          -  Subject with the following medical history (including surgical history) at screening&#xD;
             visit&#xD;
&#xD;
               1. Organ transplant or bone marrow transplant&#xD;
&#xD;
               2. History of known immunodeficiency disease or human immunodeficiency virus (HIV)&#xD;
                  infection&#xD;
&#xD;
               3. Ophthalmic surgery within 1 year before screening (including LASIK/LASEK surgery)&#xD;
&#xD;
               4. Subject who has undergone punctal occlusion and have not passed 12 weeks from the&#xD;
                  time point below.&#xD;
&#xD;
        After punctal cauterization using electrocautery. After inserting a permanent,&#xD;
        semi-permanent punctal plug. If a temporary punctal plug is inserted, remove the punctal&#xD;
        plug.&#xD;
&#xD;
          -  Subject who has administered the following drugs before the clinical trial or who need&#xD;
             to be administered during the clinical trial.&#xD;
&#xD;
               1. Cyclosporine eye drops within 6 weeks before screening&#xD;
&#xD;
               2. Ophthalmic solutions or antibiotics due to blepharitis, meibomian gland disease,&#xD;
                  herpes zoster, and eye infection within 6 weeks before screening&#xD;
&#xD;
               3. Drugs that cause dry eye within 6 weeks before screening (anticholinergics,&#xD;
                  isotretinoin, etc.)&#xD;
&#xD;
               4. Oral aspirin or drugs containing aspirin within 6 weeks before screening&#xD;
&#xD;
               5. Contains corticosteroids, mast cell stabilizers, antihistamines,&#xD;
                  anti-inflammatory drugs (NSAIDs, etc.), gamma linolenic acid, or omega-3 fatty&#xD;
                  acids within 6 weeks before screening&#xD;
&#xD;
               6. Other ophthalmic solutions within 3 days before screening&#xD;
&#xD;
          -  Subject who wears contact lenses within 1 week before screening or who needs to wear&#xD;
             them during the clinical trial&#xD;
&#xD;
          -  Subject with alcoholism or drug abuse history within 1 year before screening&#xD;
&#xD;
          -  Pregnant women, lactating women, and those who disagree with appropriate contraception&#xD;
             during the clinical trial (visit 1 to visit 6)&#xD;
&#xD;
          -  Subject with hypersensitivity to investigator's drugs or their excipients&#xD;
&#xD;
          -  Subject who participated in other clinical trials within 4 weeks before screening and&#xD;
             received/received investigator's drug or clinical trial medical devices&#xD;
&#xD;
          -  Subject judged by other investigators to be inappropriate to participate in this&#xD;
             clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jong Hyuk Jung, MS</last_name>
    <phone>82-31-739-5220</phone>
    <phone_ext>403</phone_ext>
    <email>jhjung@glpt.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Tae-Young Chung, MD, Ph D.</last_name>
    </contact>
    <investigator>
      <last_name>Dong Hui Lim, MD, Ph D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin Kwon Chung, MD, Ph D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyun-Sun Jeon, MD, Ph D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youngsub Eom, MD, Ph D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hun Lee, MD, Ph D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ho Sik Hwang, MD, Ph D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

